- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugArgenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.Fierce Biotech · 16h ago↗ source
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.Fierce Biotech · 17h ago↗ source
- Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseasesLabcorp is launching the Marker by Labcorp Genetic Health Panel, a new direct-to-consumer genetic testing tool that analyzes 163 genes to determine patients’ risk of over 100 hereditary health cond…